<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00693316</url>
  </required_header>
  <id_info>
    <org_study_id>3098001</org_study_id>
    <nct_id>NCT00693316</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability Study With Single Ascending Doses of ORM-12741</brief_title>
  <official_title>Phase I Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study With Single Ascending Doses of ORM-12741</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Orion Corporation, Orion Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Orion Corporation, Orion Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerability of escalating doses of
      ORM-12741 in healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety measures, i.e. assessing adverse events, vital signs, ECG, safety laboratory values</measure>
    <time_frame>About 8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>5 days after each dose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>ORM-12741</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ORM-12741</intervention_name>
    <description>Alternating panel single dose escalation.</description>
    <arm_group_label>ORM-12741</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Good general health ascertained by detailed medical history and physical examinations

          -  Males between 18 and 45 years

          -  Body mass index (BMI) between 18-30 kg/m2

          -  Weight 55-90 kg

        Exclusion Criteria:

          -  Evidence of clinically significant cardiovascular, renal, hepatic, haematological,
             gastro-intestinal, pulmonary, metabolic-endocrine, neurological, urogenital or
             psychiatric disease

          -  Any condition requiring regular concomitant treatment including herbal products or
             likely to need any concomitant treatment during the study

          -  Susceptibility to severe allergic reactions

          -  Regular consumption of more than 14 units of alcohol per week

          -  Current use of nicotine-containing products more than 5 cigarettes or equivalent/day

          -  Inability to refrain from using nicotine-containing products during the stay in the
             study centre

          -  Inability to refrain from consuming caffeine-containing beverages during the stay in
             the study centre

          -  Blood donation or loss of significant amount of blood within 3 months prior to the
             screening visit

          -  Abnormal finding in ECG, vital signs, laboratory tests or physical examination

          -  Participation in a drug study within 3 months prior to the start of this study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Déborah Metzger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Forenap Pharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Forenap Pharma</name>
      <address>
        <city>Rouffach</city>
        <zip>68250</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 30, 2008</study_first_submitted>
  <study_first_submitted_qc>June 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2008</study_first_posted>
  <last_update_submitted>February 10, 2010</last_update_submitted>
  <last_update_submitted_qc>February 10, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 11, 2010</last_update_posted>
  <responsible_party>
    <name_title>Jutta Hänninen, Clinical study manager</name_title>
    <organization>Orion corporation, Orion Pharma</organization>
  </responsible_party>
  <keyword>Healthy volunteer study</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

